Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Feb 25;16(2):e0247128. doi: 10.1371/journal.pone.0247128

Transcriptomic profiling and genomic mutational analysis of Human coronavirus (HCoV)-229E -infected human cells

Nehemya Friedman 1,2, Jasmine Jacob-Hirsch 3,4, Yaron Drori 1,2, Eyal Eran 3,4, Nitzan Kol 3,4, Omri Nayshool 3,4, Ella Mendelson 1,2, Gideon Rechavi 3,4, Michal Mandelboim 1,2,*
Editor: Binod Kumar5
PMCID: PMC7906355  PMID: 33630927

Abstract

Human coronaviruses (HCoVs) cause mild to severe respiratory infection. Most of the common cold illnesses are caused by one of four HCoVs, namely HCoV-229E, HCoV-NL63, HCoV-HKU1 and HCoV-OC43. Several studies have applied global transcriptomic methods to understand host responses to HCoV infection, with most studies focusing on the pandemic severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome CoV (MERS-CoV) and the newly emerging SARS-CoV-2. In this study, Next Generation Sequencing was used to gain new insights into cellular transcriptomic changes elicited by alphacoronavirus HCoV-229E. HCoV-229E-infected MRC-5 cells showed marked downregulation of superpathway of cholesterol biosynthesis and eIF2 signaling pathways. Moreover, upregulation of cyclins, cell cycle control of chromosomal replication, and the role of BRCA1 in DNA damage response, alongside downregulation of the cell cycle G1/S checkpoint, suggest that HCoV-229E may favors S phase for viral infection. Intriguingly, a significant portion of key factors of cell innate immunity, interferon-stimulated genes (ISGs) and other transcripts of early antiviral response genes were downregulated early in HCoV-229E infection. On the other hand, early upregulation of the antiviral response factor Apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) was observed. APOBEC3B cytidine deaminase signature (C-to-T) was previously observed in genomic analysis of SARS-CoV-2 but not HCoV-229E. Higher levels of C-to-T mutations were found in countries with high mortality rates caused by SARS-CoV-2. APOBEC activity could be a marker for new emerging CoVs. This study will enhance our understanding of commonly circulating HCoVs and hopefully provide critical information about still-emerging coronaviruses.

Introduction

Human coronaviruses (HCoVs), which are enveloped, positive single-stranded RNA (+ssRNA) viruses belonging to the Coronaviridae family, are associated with a wide spectrum of respiratory diseases [1, 2]. Thus far, seven types of HCoV have been discovered in humans, the majority (Alphacoronavirus species HCoV-NL63 and HCoV-229E and betacoronavirus species HCoV-HKU1 and HCoV-OC43) being causative agents of community-acquired infections. These HCoV infections occur primarily in the winter-spring season [36], however summer epidemics have been detected [7]. The other three HCoVs are the pandemic severe acute respiratory syndrome coronavirus (SARS-CoV), the Middle East respiratory syndrome coronavirus (MERS-CoV) [8] and the newly pandemic SARS-CoV-2 [9].

HCoVs typically exploit three known receptors or O-acetylated sialic acids on the host cell surface to gain entry [10]. Coronaviruses have an exceptionally large ~30 kb genome in polycistronic organization and engage a unique transcription mechanism to generate mRNA [11]. They possess many non-structural proteins (NSPs) that appear to have multiple functions in RNA processing, facilitating viral entry, gene expression and virus release [10]. Many +ssRNA viruses use diverse strategies to subvert and exploit host protein synthesis [12], with one central strategy involving inactivation of the elongation initiation complex by manipulating kinase activities. Indeed, viral replication and protein expression are associated with endoplasmic reticulum (ER) overload and subsequent stress responses which trigger host protein translation shutoff. Coronaviruses have evolved to block or subvert these responses in order to restore ER homeostasis or block apoptosis [13]. Some coronaviruses have evolved to counteract the dsRNA-activated protein kinase (PKR), which prevents translation by phosphorylating elongation initiation factor 2 (eIF2) and upregulating antiviral gene expression, including the production of interferons (IFNs) [10, 14]. Several additional innate immune receptors involved in recognizing RNA viruses activate interferon-stimulated genes (ISGs) and other cellular factors which fight the viral intruders [15].

In the last decade, several studies have focused on host cell transcriptome changes subsequent to HCoV infection. Microarray analysis in human A549 and HuH7 cells found HCoV-229E to attenuate the inducible activity of NF-κB and to restrict the nuclear concentration of NF-κB subunits [16]. Another microarray analysis of peripheral blood mononuclear cells collected from SARS-CoV patients, described the altered inflammatory and immune genes that may contribute to acute lung injury and imbalance of homeostasis [17]. Differential RNA sequencing analysis comparing SARS-CoV and MERS-CoV–infected human Calu-3 cells showed that both viruses induced a similar activation pattern of recognition receptors and of the interleukin 17 (IL-17) pathway, however, only MERS-CoV downregulated the expression of type I and II major histocompatibility complex genes [18]. Transcriptomic characteristics of SARS-CoV-2 patients identified excessive cytokine release, activation of apoptosis and of the p53 signaling pathway [19]. Global transcriptomic sequencing to shed light on the influence of common circulating HCoVs on host cells is lacking. Thus, this study used RNA-next generation sequencing (NGS) to track the transcriptomic changes in human MRC-5 cells following infection with HCoV-229E.

Results

RNA was extracted at various time points following infection of MRC-5 with HCoV-229E and viral titers were estimated both from the infected cells as well as the from culture supernatants by qPCR analysis (Fig 1A and 1B). Rapid viral propagation inside the host cells, reaches maximal levels at 24 hours post infection (HPI) and remained stable for 4 days (Fig 1A). Viral copies began to emerge in the supernatant at 24 HPI and gradually increased over time (Fig 1B). At 96 HPI, MRC-5 cell counts began to decline and the cells were not viable a day later. In parallel to the high replication rate of HCoV-229E, a robust change in the MRC-5 transcriptome was observed, with 1465 transcripts already showing a >2-fold change at 6 HPI (’early genes’) as compared to uninfected cells. The number of active genes continued to increase as infection progressed, until it reached over 5000 transcripts at 48–72 HPI (Fig 1C).

Fig 1. Change in gene expression following HCoV-229E infection.

Fig 1

(A-B) Viral propagation of HCoV-229E. MRC-5 cells, 24-hour culture to 80–90% confluency, were infected with 0.01 multiplicity of infection (MOI) of HCoV-229E virus. Cells and virus were grown in Eagle’s Minimum Essential Medium (EMEM) supplemented with 2% fetal calf serum (FCS) and incubated in a humidified incubator with 5% CO2, at 35°C. Total RNA was extracted at the indicated hours post infection (HPI) and viral load was determined in both cells (A) or growth media (B) by qPCR analysis. (C) Active transcripts in HCoV-229E –infected MRC-5 cells. Total RNA samples of MRC-5-infected cells (from section A) were prepared using the Illumina TruSeq RNA Library Preparation Kit v2 and sequenced in Illumina HiSeq 2500 Sequencer. Software and applications used for sequencing and data analysis are specified in the methods. Total number of upregulated (>2 fold change, red bars) or downregulated (<-2 fold change, blue bars) genes at the indicated HPI was calculated by comparing to gene expression to that measured in uninfected cells.

Prediction of canonical pathways based on the most significant gene enrichment included eIF2 signaling, cell cycle control of chromosomal replication, cholesterol biosynthesis superpathway, BRCA1-associated DNA damage response and other cell cycle checkpoint regulation pathways (Fig 2A). More specifically, 205 gene annotations in the NGS analysis were categorized in the eIF2 signaling pathway, of which 64.88% genes were active/inactive in MRC-5 cells. The parameter of active/inactive transcript is being significantly >2 upregulated or <-2 downregulated in fold-change as compared to uninfected cells. At early stages of infection, considerable downregulation of the eIF2 signaling pathway was observed in MRC-5 cells, a trend which increased as infection progressed (Fig 2B-I). In this pathway, over 80 genes which code for ribosomal protein subunits (RPLs and RPSs) were downregulated during infection (data not presented). The cell cycle control of chromosomal replication pathway includes genes that are involved in the strict control of DNA origin replication points. In our analysis, 57 genes were annotated to this pathway in IPA software, of which 64.91% were active/inactive in MRC-5 cells. Genes in this pathway were upregulated mostly at the early stages of HCoV-229E infection (22 genes at 6 HPI), but were later less active during the late stages of infections (Fig 2B-II). Two of the most significantly upregulated early genes in this pathway were ORC1 and CDC6, both of which initiate assembly of a pre-replication complex at DNA replication origins [20]. In the cholesterol biosynthesis pathway, 18 genes were downregulated in MRC-5 cells, 15 of which at 6 HPI (Fig 2B-III). During infection, the BRCA1 and DNA damage response pathway was active (48.75% of 80 genes) in MRC-5 cells. Many genes in the pathway were upregulated within 6–24 HPI, followed by a gradual decline in gene expression as infection persisted (Fig 2B-IV). To confirm the data of RNA-Sequencing, MRC-5 cells were infected with HCoV-229E and total RNA was extracted and analyzed by qRT-PCR for the detection of several selected mRNAs with differential expression (Fig 2C). Relative gene expression was calculated for 2 transcripts in the cell cycle control of chromosomal replication pathway, ORC1 and CDK1 mRNA (Fig 2C-I and II respectively) and one eIF2 pathway factor, ATF3 mRNA (Fig 2C-III). We found that the fold change from qPCR (Fig 2C) is correlated to fold change of from NGS analysis for these genes. Next, expression of genes involved in antiviral response were analyzed. In a database of 319 genes involved in "antiviral response", 105 were active in MRC-5 cells during HCoV-229E infection. Strikingly, as shown in Fig 3A, 82% of the antiviral genes were downregulated at 6 HPI, and 65% were downregulated genes at 24 HPI. Only at 48–72 HPI did the profile change, with 58% of the genes showing upregulated levels as compared to control cells (Fig 3A). The temporal expression of 23 early activated antiviral genes (6 HPI), as shown in Fig 3B, indicates that most of the downregulated genes remained inactive (below 2 fold change) during infection. In general, these genes included a cluster of ISGs, e.g., the transcription factors interferon regulatory factor 1 and 2 (IRF1 and IRF2) and interferon-induced protein with tetratricopeptide repeats (IFITs) family members, a major branch of the immune antiviral response [21, 22]. Furthermore, an early regulator of the response to viral RNA detection, DHX58 (also known as LPG2 or RIG-I-like receptor 3 (RLR-3)), was downregulated (-2.25 fold) following HCoV-229E infection, as was suppressor of cytokine signaling 1 (SOCS1) (-2.09 fold). SOCS1 is involved in negative regulation of cytokines that signal through the JAK/STAT pathway which induces expression of IFN-stimulated genes [23, 24]. PCR analysis of CLU transcript, one of the early antiviral response genes (Fig 3B), validated the trend of expression observed in the NGS analysis (Fig 3C).

Fig 2. Analysis of canonical pathways in HCoV-229E-infected cells.

Fig 2

(A) Canonical pathways enrichment analysis. Analysis was conducted for HCoV-229E-infected MRC-5 cells at 6 hours post-infection (HPI) as compared to uninfected cells. Canonical pathways with highest -log p-value (using Benjamini-Hochberg correction) are presented. (B) The number of activated genes was calculated for the eIF2 (I), cell cycle control of chromosomal replication (II), cholesterol biosynthesis (III) and role of BRCA1 in DNA damage response (IV) pathways. Up- and downregulated pathways are presented in red and blue, respectively. (C) Validation of gene expression. Cells were infected with HCoV-229E and total RNA was extracted and treated as described in the Methods section. Relative gene expression was calculated for ORC1 (I), CDK1 (II) mRNA (belong to cell cycle control of chromosomal replication pathway) and ATF3 (III) mRNA (belongs to eIF2 pathway). Fold-change in transcripts levels, as measured by qPCR analysis (Bars, left Y axis), was compared to the results of the NGS analysis (line, right Y axis).

Fig 3. Expression of genes involved in antiviral response following HCoV-229E infection.

Fig 3

(A) Sum of up and downregulated genes in MRC-5 cells at each time point post HCoV-229E infection are presented in red and blue, respectively. (B) Early activated antiviral response genes. Genes that were >2 or <-2 fold change in MRC-5 cells at 6 hours post HCoV-229E infection are presented in fold change heat map in following HPI. (C) Validation of gene expression. Cells were infected with HCoV-229E and total RNA was extracted and treated as described in the Methods section. Relative gene expression was calculated for CLU mRNA. Fold-change in transcripts levels, as measured by qPCR analysis (Bars, left Y axis), was compared to the results of the NGS analysis (line, right Y axis).

Apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) was upregulated in early antiviral responses in infected MRC-5 cells (Fig 3B). APOBEC3 proteins play essential roles in innate immunity by deaminating cytidine in RNA (C-to-U) and/or DNA (C-to-T), restricting foreign viral RNA/DNA [25]. Mutational analysis suggests that pandemic coronaviruses show a C-to-T signature of APOBEC activity in infected cells [26]. Thus, we analyzed genomic sequences of HCoV-229E and of the most recent outbreak of SARS-CoV-2 in search of variant viruses showing characteristics of APOBEC editing activity. We downloaded 303 partial and complete genomes of HCoV-229E obtained from clinical samples (From the ViPR database) and showed that C-to-T mutations occurred as frequently as T-to-C mutations (Fig 4A), meaning that there is no strong evidence of APOBEC editing activity in the database sequences of this specific HCoV strain. However, a first analysis of broncho-alveolar lavage fluids derived from two Wuhan patients showed nucleotide changes that may be signatures of C-to-U RNA editing [26]. In a larger analysis, using the Global Initiative for Sharing All Influenza Data GISAID SARS-CoV-2 sequence database, Korber et al. found a distinct bias for C-to-T mutations (47%) in the spike protein [27]. In order to further characterize the mutation in the whole genomic sequence of the SARS-CoV-2, 16600 SARS-CoV-2 sequences from different origins were downloaded from the hCoV-19 database and compared; 41% of the variation between the sequences were C-to-T (Fig 4B). Higher correlation was found between C-to-T occurrences and geographic regions characterized with high mortality as compared to lower mortality (R2 = 0.222, R2 = 0.065 respectively) (Fig 4C and 4D), suggesting that the new emerging CoV may use the APOBEC nucleotide editing activity to increase its virulence.

Fig 4. APOBEC mutations in HCoV-229E and SARS-CoV-2.

Fig 4

(A-B) Mutation analysis of CoVs genomes. Percentage of all types of nucleotide transitions (mutation frequency >0.1) are presented in pie charts for HCoV-229E (A) and SARS-CoV-2 (B). (C-D) Correlation between independently occurring C-to-T events and the number of countries with mutations at the specific site. (C) Correlation in countries with moderate SARS-CoV-2 mortality (<99 deaths per million). (D) Correlation in countries with high SARS-CoV-2 mortality (> 99 deaths per million). Y-axis indicates the number of C-to-T alterations identified as independent events on the phylogenetic tree analysis. X-axis indicates the number of countries in which the event was identified in at least in one corona sample.

Discussion

This study sought to shed light on host transcriptome responses to common infecting HCoVs, using NGS and bioinformatics tools. More specifically, it aimed to examine major transcriptomic changes occurring over several cycles of HCoV-229E infection in human host cells. Several cellular pathways that were affected early in infection were identified, i.e., eIF2 signaling, cell cycle, cholesterol biosynthesis, BRCA1-associated DNA damage response and cellular innate immune factors.

The fluidity of membranes is dependent on the presence and structure of specific lipids and sterols. While cholesterol increases membrane fluidity by interfering with the packing of acyl chains, it can also reduce the flexibility of neighboring unsaturated acyl chains [28, 29]. Viruses may remodel lipid metabolism and membrane structure to form a microenvironment suitable for infection [29]. Lipidomic analyses have uncovered a striking rearrangement of fatty acids and phospholipids in the cellular membrane upon HCoV-229E and MERS-CoV infection [30, 31]. The current NGS analysis indicated that the cholesterol biosynthesis pathway is inhibited in multiple steps both at early and late stages following HCoV-229E infection (Fig 2A and 2B-III). Cholesterol can promote coronavirus murine hepatitis virus (MHV) entry to the cells [29]. When cholesterol was depleted by methyl β-cyclodextrin (MβCD) or supplemented in growth media, it reduced or increased cells susceptibility to MHV respectively [32]. These various cholesterol levels are correlated with S-protein-mediated membrane fusion rather than binding activities [32]. HCoV-229E binds to CD13 in lipid rafts and enters the cell through caveolae [33]. Depletion of plasma membrane cholesterol by MβCD disrupted the co-localization of HCoV-229E and caveolin-1 and decreased the intracellular occurrence of HCoV-229E [33]. Both SARS-CoV-1 and SARS-CoV-2 S proteins bind the host cell receptor ACE2 [34]. This receptor is localized in cholesterol-rich microdomains, which are important for the efficient interaction of the S protein with ACE2 [35]. Depletion of plasma membrane cholesterol with MβCD in Vero E6 cells relocalized the raft-resident marker caveolin-1 as well as ACE2 to a non-raft environment, and inhibited infectivity of the virus [36]. Intriguingly, cholesterol depletion by pretreatment of Vero E6 cells with MβCD reduced the release of SARS-CoV particles and the levels of viral mRNAs were significantly decreased. However, cholesterol depletion at the post-entry stage (3 HPI) caused only a limited effect on virus particle release [37]. It remains to be determined if inhibition of the cholesterol biosynthesis superpathway in MRC-5 cells is an attempt of the host to interfere with HCoV-229E infection, or a response of the virus to establish a suitable environment for infection. If the cholesterol biosynthesis superpathway is inhibited, the basic acetyl-CoA molecule could be directed to other metabolic or synthetic pathways.

Acetyl-CoA is a major substrate used in the transfer of acetyl groups to lysine residues of histones, which results in increased accessibility of chromatin to DNA-binding proteins to the exposed sites, where they can then activate gene transcription [38]. In HCoV-229E-infected MRC-5 cells, changes in several pathways that could be linked together were observed, i.e., cell cycle regulation, control of chromosomal replication and the role of BRCA1 in DNA damage response. Cell cycle control of the chromosomal replication pathway refers to the strict control of the chromosomal origin of replication. This pathway includes the six-subunit origin recognition complex (ORC), cell division control protein 6 (Cdc6) AAA+ ATPase, minichromosome maintenance (MCM) protein complex, cyclin-dependent protein kinases (CDKs) and others [39]. Marked upregulation of this pathway was observed in early stages of HCoV-229E infection. Exploitation of host ORC has been extensively described in Epstein–Barr virus (EBV) infection, where the virus utilizes its own EBNA1 to recruit host replication initiation machinery [40, 41]. Similarly, coronaviruses manipulate the cell at various stages, which can differ between the specific coronaviruses and even between host cell types [10]. In the present analysis, upregulation of cyclins and cell cycle regulation pathway was observed, together with downregulation of checkpoint regulation Growth 1 (G1) to Synthesis (S) phases, implying that cells enter the DNA synthesis phase. Functional annotation analysis supported these observations, where "Interphase", "Segregation of chromosomes", "G1/S phase transition", "S phase" and "M phase" annotations were upregulated at 6 HPI in MRC-5 cells (data not presented, IPA software). Many DNA and RNA viruses are known to manipulate cell cycle at different stages, in efforts to increase the efficiency of virus replication by subverting host-cell functions [42]. This action is not restricted to DNA viruses or retroviruses, which primarily replicate in the nucleus, but also RNA viruses, which mainly replicate in the cytoplasm [43]. For instance, infection with measles, a negative ssRNA viruses, leads to cell arrest in G0 stage [44] and simian parainfluenza virus 5 (SV5) promotes prolonged G1 and G2 phases [45]. The positive-ssRNA avian coronavirus infectious bronchitis virus (IBV) was shown to induce cell cycle arrest at both S and G2/M phases for the enhancement of viral replication and progeny production [4648]. Betacoronavirus MHV infection causes decreased hyperphosphorylation of the retinoblastoma protein (pRb), resulting in arrest of cell cycle progression from G1 to S [49]. Transient expression of the SARS-CoV 3a structural protein inhibits cell growth and prevents 5-bromodeoxyuridine incorporation, suggesting that it inhibits cell cycle progression [50]. The current analysis suggests that HCoV-229E causes cell cycle arrest mainly in S phase that could benefits from this cellular recruitment for chromosomal replication.

As MRC-5 cells enter DNA replication stage during HCoV-229E infection, mutations can occur. Accordingly, upregulation of BRCA1-associated DNA damage response was observed. To avoid passage of accumulated DNA damage to daughter cells, cell cycle checkpoints are activated to regulate cell growth and division, allowing cells to repair the damage before resuming cell cycle progression [51]. DNA damage activates the kinases ATM, ATR and CHK2, which, in turn, activate BRCA1 by phosphorylation [52]. The tumor repressor BRCA1 is recruited to DNA damage sites, promotes DNA damage checkpoint activation and DNA damage repair [51, 53]. BRCA1 has been suggested to be responsible for or involved in the activation for G1/S, S-phase and G2/M checkpoints [5356]. Activation of the ATR-dependent cellular DNA damage response is one of the mechanisms exploited by IBV to induce cell cycle S-phase arrest [46]. Activation of the cellular DNA damage response by the gammacoronavirus infectious bronchitis virus (IBV) causes cell cycle arrest in the S phase, thereby upregulating DNA replication factors in the cytoplasm, which are exploited for viral replication [10, 46].

Translation is a key step in the regulation of gene expression and one of the most energy-consuming processes in the cell. In homeostasis, the eIF2 machinery actively participates in the regulation of protein synthesis and its dysregulation is thought to contribute to pathological conditions [57]. While proper synthesis is crucial for the innate antiviral immune response, viruses rely on the host translation machinery and directly interfere with the function of transcription factors or with signaling pathways that regulate translation, to favor synthesis of viral proteins [12]. Coronaviruses modulate host protein synthesis through different mechanisms, which contributes to their pathogenicity [10]. Like other viruses, coronaviruses overload the ER with the production of viral proteins, thus triggering an ER stress response. SARS-CoV, MHV, IBV and TGEV intervene with ER stress and eIF2 regulators to ensure continuous production of functional viral proteins [13]. In the current study, downregulation of the eIF2 signaling pathway occurred at early stages of HCoV-229E infection. This is assume to be in response to the robust growth of HCoV-229E inside the cells (Fig 1A), which presumably causes ER overload at early stages of infection, thereby triggering a stress response, including manipulation of eIF2 signaling (Fig 2B-I), as reported for other CoVs [13].

Viral dsRNA and 5′-triphosphate-RNA molecules are present in the cytosol and recognized by intracellular sensors. These sensors activate signaling pathways that generally activate IFN-regulatory factors (IRFs) and NF-κB. The latter triggers the excretion of cytokines and Type-I IFN, which activate JAK-STAT signaling, which, in turn, induces expression of antiviral ISGs [58, 59]. Since the present NGS analysis identified broad downregulation of ISG transcripts (Fig 3), it can be assumed that the HCoV infection interfered with upstream regulators of IFN transcription. Indeed, downregulation of IRF1 and IRF2 transcription factors (Fig 3B), which are responsible for inducing the expression of IFNs and pro-inflammatory cytokines [60], and which are necessary for positive regulation of Toll-like receptor 3 transcription that recognizes dsRNA [22, 6163], was observed. Similarly microarray analysis of an acute case of SARS-CoV revealed upregulation of pro- and anti-inflammatory signals and downregulation of many IFN-stimulated genes [17]. Upregulation of APOBEC3B was demonstrated in the early stages of HCoV-229E infection (Fig 3B). Induction of APOBEC3 family members is augmented by IFN-α [64]. APOBEC3B is a DNA cytidine deaminase that prevents interspecies DNA transmission by conversion of cytosines of foreign DNA to uracil, leading to hypermutations [6567]. RNA editing activity of this cytidine deaminase was first demonstrated in human immunodeficiency virus (HIV) and later in measles, mumps and respiratory syncytial virus (RSV) [68, 69]. Upregulation of several APOBEC3 transcripts was observed in cultured human airway epithelium (HAE) cells following HCoV-NL63 infection. More specifically, three APOBEC family proteins (A3C, A3F and A3H) inhibited viral infection in vitro but did not cause hypermutation of the HCoV-NL63 genome [70]. Viral RNA sequencing and mutational analysis has suggested that both APOBEC and adenosine deaminase acting on RNA (ADAR) deaminases are involved in SARS-CoV, MERS-CoV and SARS-CoV-2 genome editing [26]. The present analysis showed that the mutational imprint of APOBEC proteins is less distinct in commonly infecting HCoV-229E, which have been circulating for several decades [70] (Fig 4). The upregulation of APOBEC3B in early stages of HCoV-229E infection (Fig 3B) could be associated with the kinetics of viral copies that are found in and out of the host cells (Fig 1), however, the lake in APOBEC C-toT editing activity in HCoV-229E genome (Fig 4) may imply an evasion mechanism of the virus from this mutational mechanism. On the other hand, APOBEC proteins may cause antigenic drift that shapes the spread of new pandemic CoVs [26] (Fig 4).

This work used NGS and bioinformatics approaches to demonstrate the influence of HCoV-229E on the host cell transcriptome. Several pathways that were altered were discussed, mainly involving alterations of the host cell cycle regulation, metabolic processes, protein synthesis machinery and cellular innate antiviral responses. This study provides important data and expands our current understanding of the pathology and treatment targets of common HCoVs and newly emerging Coronaviridae.

Methods

Viruses and cell cultures

HCoV-229E virus was purchased from ATCC (VR740™) along with its recommended human host cell lines MRC-5. Cells were grown in Eagle’s Minimum Essential Medium (EMEM) supplemented with 10% fetal calf serum (FCS). After a 24-hour culture to 80–90% confluency, cells were infected with 0.01 multiplicity of infection (MOI) of virus. HCoV-229E was grown in a humidified incubator with 5% CO2, at 35°C. Cells and virus were incubated for 2–7 days as per the manufacturer recommendations.

RNA extraction and preparation

Total RNA was extracted at 0, 6, 24, 48, 72 and 96 hours post-HCoV-229E infection, using NucliSENS® easyMag®, according to the manufacturer’s protocol. At each time point, three biological repeats were tested. All RNA samples were treated with RQ1 RNase-free DNaseI (Promega, USA), according to the manufacturer’s protocol. RNA quality was assessed using the Agilent High Sensitivity RNA ScreenTape for TapeStation System (Agilent Technologies, Germany).

Real-time quantitative reverse transcription–polymerase chain reaction (qRT-PCR)

Viral load in both supernatants and cells was determined as described by Dare et al. [71]. Validation of gene expression was performed using SensiFAST™ SYBR® Lo-ROX One-Step Kit, according to the manufacturer’s instructions (Bioline Reagents Ltd). The primers used for validations were as follow: ORC1: F-5’-AGAGCCATCCTCGCAGAGTT, R-5’-GCAGTCCCTCCATTCTGCAC; CLU: F-5’-GAAGAGCGCAAGACACTGCT, R-5’-CAGACGCGTGCGTAGAACTT; CDK1: F-5’-TTGGCCTTGCCAGAGCTTTT, R-5’-CGAGCTGACCCCAGCAATAC. ATF3: F-5’-CGGAGTGCCTGCAGAAAGAG, R-5’-GTGGGCCGATGAAGGTTGAG. Relative gene expression was calculated using the 2-ΔΔCt method [72].

RNA preparation, sequencing and data analysis

For NGS analysis the RNA samples (>8 RNA integrity number (RIN)) were prepared using the Illumina TruSeq RNA Library Preparation Kit v2 and sequenced in Illumina HiSeq 2500 Sequencer. Software and applications used for sequencing and data analysis were as follows: library quality control: FASTQC version 0.11.5, quality and adapter trimming: trim_galore (uses cutadapt version 1.10), mapping: Tophat2 version 2.1.0 (uses Bowtie2 version 2.2.6), gene counting: HTseq-count version 0.6.1/0.11.2, normalization and differential expression analysis: DESeq2 R package version 1.18.1. Sequencing and quality control were conducted by the Technion Genome Center (TGC). Data analysis was performed using QIAGEN Ingenuity Pathway Analysis (QIAGEN IPA) software. Transcriptomic reads at each time point were compared to the uninfected cells. A transcript is considered active or inactive if it significantly upregulated >2 fold-change or downregulated <-2 fold-change. Canonical pathways were analyzed with highest–log(p-value) (significance of gene enrichment for any given pathway) and highest z-score (directional effect). Diseases and Functions Analysis in IPA software predicts cellular processes and biological functions based on gene expression and predicts directional change on that effect (IPA manual). A database of 319 "antiviral response"–annotated genes were pooled from the IPA database and compared to the collected transcriptome dataset. TIBCO Spotfire version 7.7.0.39 was used for data analysis, filtering and visualization, including heatmap generation. Whole genomic sequences of the SARS-CoV-2 were downloaded from the hCoV-19 data base (GSAID; more than 16600 sequences, at May 12 2020). Sequences of HCoV-229E were obtained from the NIAID Virus Pathogen Database and Analysis Resource (ViPR) [73] through the web site at http://www.viprbrc.org/. For genomic analysis we used the bioinformatics toolkit Augur (https://nextstrain-augur.readthedocs.io/en/stable/).

This work was performed in partial fulfillment of the requirements for a Ph.D. degree of Nehemya Friedman, Sackler Faculty of Medicine, Tel Aviv University, Israel.

Data Availability

RNA-Seq library is available in the GEO repository (Accession number GSE155986).

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Geller C, Varbanov M, Duval RE. Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies. Viruses. 2012;4(11):3044–68. 10.3390/v4113044 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Razuri H, Malecki M, Tinoco Y, Ortiz E, Guezala MC, Romero C, et al. Human Coronavirus-Associated Influenza-Like Illness in the Community Setting in Peru. Am J Trop Med Hyg. 2015;93(5):1038–40. 10.4269/ajtmh.15-0271 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gerna G, Campanini G, Rovida F, Percivalle E, Sarasini A, Marchi A, et al. Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients. J Med Virol. 2006;78(7):938–49. 10.1002/jmv.20645 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Gerna G, Percivalle E, Sarasini A, Campanini G, Piralla A, Rovida F, et al. Human respiratory coronavirus HKU1 versus other coronavirus infections in Italian hospitalised patients. J Clin Virol. 2007;38(3):244–50. 10.1016/j.jcv.2006.12.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Vabret A, Dina J, Gouarin S, Petitjean J, Tripey V, Brouard J, et al. Human (non-severe acute respiratory syndrome) coronavirus infections in hospitalised children in France. J Paediatr Child Health. 2008;44(4):176–81. 10.1111/j.1440-1754.2007.01246.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Gaunt ER, Hardie A, Claas EC, Simmonds P, Templeton KE. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol. 2010;48(8):2940–7. 10.1128/JCM.00636-10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Friedman N, Alter H, Hindiyeh M, Mendelson E, Shemer Avni Y, Mandelboim M. Human Coronavirus Infections in Israel: Epidemiology, Clinical Symptoms and Summer Seasonality of HCoV-HKU1. Viruses. 2018;10(10). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.King Andrew, Lefkowitz Elliot, Adams Michael J., Carstens Eric B. Virus Taxonomy - 1st Edition. Elsevier. 2017. [Google Scholar]
  • 9.Viruses CSGotICoTo. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–44. 10.1038/s41564-020-0695-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. Host Factors in Coronavirus Replication. Curr Top Microbiol Immunol. 2018;419:1–42. 10.1007/82_2017_25 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Sola I, Almazán F, Zúñiga S, Enjuanes L. Continuous and Discontinuous RNA Synthesis in Coronaviruses. Annu Rev Virol. 2015;2(1):265–88. 10.1146/annurev-virology-100114-055218 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Walsh D, Mohr I. Viral subversion of the host protein synthesis machinery. Nat Rev Microbiol. 2011;9(12):860–75. 10.1038/nrmicro2655 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Fung TS, Liao Y, Liu DX. Regulation of Stress Responses and Translational Control by Coronavirus. Viruses. 2016;8(7). 10.3390/v8070184 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Wang X, Liao Y, Yap PL, Png KJ, Tam JP, Liu DX. Inhibition of protein kinase R activation and upregulation of GADD34 expression play a synergistic role in facilitating coronavirus replication by maintaining de novo protein synthesis in virus-infected cells. J Virol. 2009;83(23):12462–72. 10.1128/JVI.01546-09 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Jensen S, Thomsen AR. Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. J Virol. 2012;86(6):2900–10. 10.1128/JVI.05738-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Poppe M, Wittig S, Jurida L, Bartkuhn M, Wilhelm J, Müller H, et al. The NF-κB-dependent and -independent transcriptome and chromatin landscapes of human coronavirus 229E-infected cells. PLoS Pathog. 2017;13(3):e1006286. 10.1371/journal.ppat.1006286 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Yu SY, Hu YW, Liu XY, Xiong W, Zhou ZT, Yuan ZH. Gene expression profiles in peripheral blood mononuclear cells of SARS patients. World J Gastroenterol. 2005;11(32):5037–43. 10.3748/wjg.v11.i32.5037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Josset L, Menachery VD, Gralinski LE, Agnihothram S, Sova P, Carter VS, et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. mBio. 2013;4(3):e00165–13. 10.1128/mBio.00165-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect. 2020;9(1):761–70. 10.1080/22221751.2020.1747363 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Speck C, Chen Z, Li H, Stillman B. ATPase-dependent cooperative binding of ORC and Cdc6 to origin DNA. Nat Struct Mol Biol. 2005;12(11):965–71. 10.1038/nsmb1002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Mears HV, Sweeney TR. Better together: the role of IFIT protein-protein interactions in the antiviral response. J Gen Virol. 2018;99(11):1463–77. 10.1099/jgv.0.001149 [DOI] [PubMed] [Google Scholar]
  • 22.Sun L, Jiang Z, Acosta-Rodriguez VA, Berger M, Du X, Choi JH, et al. HCFC2 is needed for IRF1- and IRF2-dependent. J Exp Med. 2017;214(11):3263–77. 10.1084/jem.20161630 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol. 2001;21(10):3547–57. 10.1128/MCB.21.10.3547-3557.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Nan Y, Wu C, Zhang YJ. Interplay between Janus Kinase/Signal Transducer and Activator of Transcription Signaling Activated by Type I Interferons and Viral Antagonism. Front Immunol. 2017;8:1758. 10.3389/fimmu.2017.01758 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Conticello SG. The AID/APOBEC family of nucleic acid mutators. Genome Biol. 92008. p. 229. 10.1186/gb-2008-9-6-229 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Giorgio SD, Martignano F, Torcia MG, Mattiuz G, Conticello SG. Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2. Sci Adv. 2020. June 17;6(25):eabb5813. 10.1126/sciadv.abb5813 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020. Aug;182(4):812–827.e19. 10.1016/j.cell.2020.06.043 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Yeagle PL. Cholesterol and the cell membrane. Biochim Biophys Acta. 1985;822(3–4):267–87. 10.1016/0304-4157(85)90011-5 [DOI] [PubMed] [Google Scholar]
  • 29.Holthuis JC, Menon AK. Lipid landscapes and pipelines in membrane homeostasis. Nature. 2014;510(7503):48–57. 10.1038/nature13474 [DOI] [PubMed] [Google Scholar]
  • 30.Yan B, Chu H, Yang D, Sze KH, Lai PM, Yuan S, et al. Characterization of the Lipidomic Profile of Human Coronavirus-Infected Cells: Implications for Lipid Metabolism Remodeling upon Coronavirus Replication. Viruses. 2019;11(1). 10.3390/v11010073 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Mayer KA, Stöckl J, Zlabinger GJ, Gualdoni GA. Hijacking the Supplies: Metabolism as a Novel Facet of Virus-Host Interaction. Front Immunol. 2019;10:1533. 10.3389/fimmu.2019.01533 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Thorp EB, Gallagher TM. Requirements for CEACAMs and cholesterol during murine coronavirus cell entry. J Virol. 2004;78(6):2682–92. 10.1128/jvi.78.6.2682-2692.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Nomura R, Kiyota A, Suzaki E, Kataoka K, Ohe Y, Miyamoto K, et al. Human coronavirus 229E binds to CD13 in rafts and enters the cell through caveolae. J Virol. 2004;78(16):8701–8. 10.1128/JVI.78.16.8701-8708.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Sturley S, Rajakumar T, Hammond N, Higaki K, Márka Z, Márka S, et al. Potential COVID-19 therapeutics from a rare disease: Weaponizing lipid dysregulation to combat viral infectivity. J Lipid Res. 2020. 10.1194/jlr.R120000851 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Glende J, Schwegmann-Wessels C, Al-Falah M, Pfefferle S, Qu X, Deng H, et al. Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2. Virology. 2008;381(2):215–21. 10.1016/j.virol.2008.08.026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Lu Y, Liu DX, Tam JP. Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. Biochem Biophys Res Commun. 2008;369(2):344–9. 10.1016/j.bbrc.2008.02.023 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Li GM, Li YG, Yamate M, Li SM, Ikuta K. Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle. Microbes Infect. 2007;9(1):96–102. 10.1016/j.micinf.2006.10.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Burgio G, Onorati MC, Corona DF. Chromatin remodeling regulation by small molecules and metabolites. Biochim Biophys Acta. 2010;1799(10–12):671–80. 10.1016/j.bbagrm.2010.05.007 [DOI] [PubMed] [Google Scholar]
  • 39.Diffley JF, Labib K. The chromosome replication cycle. J Cell Sci. 2002;115(Pt 5):869–72. [DOI] [PubMed] [Google Scholar]
  • 40.Yoon JH, Prakash S, Prakash L. Genetic control of translesion synthesis on leading and lagging DNA strands in plasmids derived from Epstein-Barr virus in human cells. mBio. 2012;3(5):e00271–12. 10.1128/mBio.00271-12 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Shen Z. The origin recognition complex in human diseases. Biosci Rep. 2013;33(3). 10.1042/BSR20130036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Bagga S, Bouchard MJ. Cell cycle regulation during viral infection. Methods Mol Biol. 2014;1170:165–227. 10.1007/978-1-4939-0888-2_10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Emmett SR, Dove B, Mahoney L, Wurm T, Hiscox JA. The cell cycle and virus infection. Methods Mol Biol. 2005;296:197–218. 10.1385/1-59259-857-9:197 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Naniche D, Reed SI, Oldstone MB. Cell cycle arrest during measles virus infection: a G0-like block leads to suppression of retinoblastoma protein expression. J Virol. 1999;73(3):1894–901. 10.1128/JVI.73.3.1894-1901.1999 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Lin GY, Lamb RA. The paramyxovirus simian virus 5 V protein slows progression of the cell cycle. J Virol. 2000;74(19):9152–66. 10.1128/jvi.74.19.9152-9166.2000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Xu LH, Huang M, Fang SG, Liu DX. Coronavirus infection induces DNA replication stress partly through interaction of its nonstructural protein 13 with the p125 subunit of DNA polymerase δ. J Biol Chem. 2011;286(45):39546–59. 10.1074/jbc.M111.242206 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Chen H, Wurm T, Britton P, Brooks G, Hiscox JA. Interaction of the coronavirus nucleoprotein with nucleolar antigens and the host cell. J Virol. 2002;76(10):5233–50. 10.1128/jvi.76.10.5233-5250.2002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Wurm T, Chen H, Hodgson T, Britton P, Brooks G, Hiscox JA. Localization to the nucleolus is a common feature of coronavirus nucleoproteins, and the protein may disrupt host cell division. J Virol. 2001;75(19):9345–56. 10.1128/JVI.75.19.9345-9356.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Chen CJ, Makino S. Murine coronavirus replication induces cell cycle arrest in G0/G1 phase. J Virol. 2004;78(11):5658–69. 10.1128/JVI.78.11.5658-5669.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Yuan X, Yao Z, Wu J, Zhou Y, Shan Y, Dong B, et al. G1 phase cell cycle arrest induced by SARS-CoV 3a protein via the cyclin D3/pRb pathway. Am J Respir Cell Mol Biol. 2007;37(1):9–19. 10.1165/rcmb.2005-0345RC [DOI] [PubMed] [Google Scholar]
  • 51.Wu J, Lu LY, Yu X. The role of BRCA1 in DNA damage response. Protein Cell. 2010;1(2):117–23. 10.1007/s13238-010-0010-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene. 2006;25(43):5864–74. 10.1038/sj.onc.1209874 [DOI] [PubMed] [Google Scholar]
  • 53.Hartwell LH, Kastan MB. Cell cycle control and cancer. Science. 1994;266(5192):1821–8. 10.1126/science.7997877 [DOI] [PubMed] [Google Scholar]
  • 54.Fabbro M, Savage K, Hobson K, Deans AJ, Powell SN, McArthur GA, et al. BRCA1-BARD1 complexes are required for p53Ser-15 phosphorylation and a G1/S arrest following ionizing radiation-induced DNA damage. J Biol Chem. 2004;279(30):31251–8. 10.1074/jbc.M405372200 [DOI] [PubMed] [Google Scholar]
  • 55.Xu B, Kim St, Kastan MB. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol. 2001;21(10):3445–50. 10.1128/MCB.21.10.3445-3450.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Cuddihy AR, O’Connell MJ. Cell-cycle responses to DNA damage in G2. Int Rev Cytol. 2003;222:99–140. 10.1016/s0074-7696(02)22013-6 [DOI] [PubMed] [Google Scholar]
  • 57.Roux PP, Topisirovic I. Signaling Pathways Involved in the Regulation of mRNA Translation. Mol Cell Biol. 2018;38(12). 10.1128/MCB.00070-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol. 2011;1(6):519–25. 10.1016/j.coviro.2011.10.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–39. 10.1007/s00281-017-0629-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Gack MU. Mechanisms of RIG-I-like receptor activation and manipulation by viral pathogens. J Virol. 2014;88(10):5213–6. 10.1128/JVI.03370-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Heinz S, Haehnel V, Karaghiosoff M, Schwarzfischer L, Müller M, Krause SW, et al. Species-specific regulation of Toll-like receptor 3 genes in men and mice. J Biol Chem. 2003;278(24):21502–9. 10.1074/jbc.M301476200 [DOI] [PubMed] [Google Scholar]
  • 62.Ren G, Cui K, Zhang Z, Zhao K. Division of labor between IRF1 and IRF2 in regulating different stages of transcriptional activation in cellular antiviral activities. Cell Biosci. 2015;5:17. 10.1186/s13578-015-0007-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Nhu QM, Cuesta N, Vogel SN. Transcriptional regulation of lipopolysaccharide (LPS)-induced Toll-like receptor (TLR) expression in murine macrophages: role of interferon regulatory factors 1 (IRF-1) and 2 (IRF-2). J Endotoxin Res. 2006;12(5):285–95. 10.1179/096805106X118834 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Peng G, Lei KJ, Jin W, Greenwell-Wild T, Wahl SM. Induction of APOBEC3 family proteins, a defensive maneuver underlying interferon-induced anti-HIV-1 activity. J Exp Med. 2006;203(1):41–6. 10.1084/jem.20051512 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol. 2010;17(2):222–9. 10.1038/nsmb.1744 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Yu Q, Chen D, König R, Mariani R, Unutmaz D, Landau NR. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem. 2004;279(51):53379–86. 10.1074/jbc.M408802200 [DOI] [PubMed] [Google Scholar]
  • 67.Ooms M, Krikoni A, Kress AK, Simon V, Münk C. APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1. J Virol. 2012;86(11):6097–108. 10.1128/JVI.06570-11 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Bishop KN, Holmes RK, Sheehy AM, Malim MH. APOBEC-mediated editing of viral RNA. Science. 2004;305(5684):645. 10.1126/science.1100658 [DOI] [PubMed] [Google Scholar]
  • 69.Fehrholz M, Kendl S, Prifert C, Weissbrich B, Lemon K, Rennick L, et al. The innate antiviral factor APOBEC3G targets replication of measles, mumps and respiratory syncytial viruses. J Gen Virol. 2012;93(Pt 3):565–76. 10.1099/vir.0.038919-0 [DOI] [PubMed] [Google Scholar]
  • 70.Milewska A, Kindler E, Vkovski P, Zeglen S, Ochman M, Thiel V, et al. APOBEC3-mediated restriction of RNA virus replication. Sci Rep. 2018;8(1):5960. 10.1038/s41598-018-24448-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Dare RK, Fry AM, Chittaganpitch M, Sawanpanyalert P, Olsen SJ, Erdman DD. Human coronavirus infections in rural Thailand: a comprehensive study using real-time reverse-transcription polymerase chain reaction assays. J Infect Dis. 2007;196(9):1321–8. 10.1086/521308 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Rao X, Huang X, Zhou Z, Lin X. An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis. Biostat Bioinforma Biomath. 2013;3(3):71–85. [PMC free article] [PubMed] [Google Scholar]
  • 73.Pickett BE, Sadat EL, Zhang Y, Noronha JM, Squires RB, Hunt V, et al. ViPR: an open bioinformatics database and analysis resource for virology research. Nucleic Acids Res. 2012;40(Database issue):D593–8. 10.1093/nar/gkr859 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Binod Kumar

4 Jan 2021

PONE-D-20-36572

Transcriptomic profiling and genomic mutational analysis of Human corona virus (HCoV)-229E -infected human cells

PLOS ONE

Dear Dr. Mandelboim,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Feb 14 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Binod Kumar, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.Thank you for stating the following financial disclosure:

 "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

At this time, please address the following queries:

  1. Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

  2. State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

  3. If any authors received a salary from any of your funders, please state which authors and which funders.

  4. If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Title and other places in the manuscript: Please change 'corona virus' to 'coronavirus'

Abstract: HCoV-229E favors S phase for viral infection - Not enough data to substantiate this claim

Line 87- change 'MCR5' to 'MCR-5' - also throughout the manuscript

Line 88- hours post infection (hpi)

Line 88- change several days to 4 days

Line 89- It is important to clearly mention here that viral titers were estimated both from the (A) infected cells as well as the from (B) culture supernatants

Line 90- mention here that the canonical pathway analysis is done for the 6 hpi timepoint. Include some background, or even a little methodological detail here.

Line 99- What parameter do you use to distinguish between active and inactive genes? Fig 2B shows only active genes

Line 101- 'which are coding to' replace by 'which code for'

Line 105- but were later less active?

Line 106- mention here that the fold change from qPCR is correlated to fold change from NGS (include correlation coefficient if applicable)

Line 118- The genes not identified- are some of them not present in MCR-5 cells?

Line 123- Do you (and how) define inactive genes from the NGS analysis? Or only from qPCR data?

Line 135- Mention the pattern

Line 139- Does this mean that there is no evidence of editing in the database sequences?

Line 140- 'that may be signatures of RNA editing' signatures of C-to-T RNA editing?

Line 145- Since the database analysis suggests that C-to-T editing by APOBEC is more characteristic of SARS-CoV-2 rather than HCoV-229E, is this a strain specific effect observed here?

Line 206- data to substantiate this claim?

Line 375 and 377- Journal details missing

Line 481- and incubated

Reviewer #2: This is a very useful Research Article providing insights in alterations of transcriptomics in MRC5 cells that have been infected with HCoV-229E.

Provided data and their discussion are intelligible and interesting. The conception of the conducted research is original and helpful.

Appropriated controls are used and conclusions are based on the presented data and the annotated bibliography.

All data are fully available and well described in the figures.

I would like to indicate some possible additional considerations, for example at line 161 it might be useful to commend on the cholesterol biosynthesis pathway being downregulated both at early and late stages following HCoV-229E infection.

Could the upregulation of APOBEC3B (as antiviral reflection) in early stages of HCoV-229E infection be associated with the kinetics of viral copies that are found in and out of the host cells?

The Research Article is a thorough effort to document transcriptomic changes after HCoV-229E infection, that is being considered a "benign" infection.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Feb 25;16(2):e0247128. doi: 10.1371/journal.pone.0247128.r002

Author response to Decision Letter 0


28 Jan 2021

Response to Reviewers

Our sincere gratitude for your dedication and diligent work! We thank for the opportunity to learn from your experience and your constructive comments.

Reviewer #1

Comment 1

Title and other places in the manuscript: Please change 'corona virus' to 'coronavirus'

Answer 1

'Corona virus' in the title and in line 135 were corrected to 'coronavirus'

Comment 2

Abstract: HCoV-229E favors S phase for viral infection - Not enough data to substantiate this claim

Answer 2

Indeed, this is a statement that is not supported by cell cycle analysis and should rather be phrased as an assumption or suggestion. Thus, we added the word 'may' to the sentence: "…suggest that HCoV-229E may favors S phase for viral infection" .

Comment 3

Line 87- change 'MCR5' to 'MCR-5' - also throughout the manuscript

Answer 3

All 23 "MRC5" were changed to "MCR-5".

Comment 4

Line 88- hours post infection (hpi)

Answer 4

Certainly, it is not sufficient that the meaning of this acronym appears only in the methods and it also must be at the first time it appears in the results.

Comment 5

Line 88- change several days to 4 days

Answer 5

Corrected.

Comment 6

Line 89- It is important to clearly mention here that viral titers were estimated both from the (A) infected cells as well as the from (B) culture supernatants

Answer 6

Sentences were rephrased to emphasize this description:

"RNA was extracted at various time points following infection of MRC-5 with HCoV-229E and viral titers were estimated both from the infected cells as well as the from culture supernatants by qPCR analysis (Fig 1A-B). Rapid viral propagation inside the host cells, reaches maximal levels at 24 hours post infection (HPI) and remained stable for 4 days (Fig 1A)."

Comment 7

Line 90- mention here that the canonical pathway analysis is done for the 6 hpi timepoint. Include some background, or even a little methodological detail here.

Answer 7

The canonical pathway analysis was done for all time points. We focused at 6 HPI only on early activated antiviral genes (Figure 3B) (lines 121-123)

Comment 8

Line 99- What parameter do you use to distinguish between active and inactive genes? Fig 2B shows only active genes

Answer 8

The parameter is of active/inactive transcript is being significantly >2 upregulated or <-2 downregulated in fold-change as compared to uninfected cells. We added this information in the text next to the sentence in line 99 and in the methods. Thank you for emphasizing this point.

Comment 9

Line 101- 'which are coding to' replace by 'which code for'

Answer 9

This sentence was corrected.

Comment 10

Line 105- but were later less active?

Answer 10

Thank you for this comment. You are correct. We sorry for using an inappropriate term and replaced the word "lightly" to "were later less".

Comment 11

Line 106- mention here that the fold change from qPCR is correlated to fold change from NGS (include correlation coefficient if applicable)

Answer 11

Thank you for this comment. It is a very important remark and we added it to the manuscript.

Comment 12

Line 118- The genes not identified- are some of them not present in MCR-5 cells?

Answer 12

Indeed, some genes may be present in immune cells however some of these genes may have low copies number, thus had nonsignificant p-value and were excluded from downstream analysis. Mentioning the "256 genes" does not contribute to the discussion and may even be misleading, thus we deleted it.

Comment 13

Line 123- Do you (and how) define inactive genes from the NGS analysis? Or only from qPCR data?

Answer 13

See comment/answer 8.

All the data and calculations were performed on NGS analysis. qPCR was used only to validated gene expression of selected genes.

Comment 14

Line 135- Mention the pattern

Answer 14

Since we wanted to quantify point mutations in the virus genome and avoided the calculation of mutation patterns, we rephrased the citation from "show a pattern of APOBEC activity" to "show a C-to-T signature of APOBEC activity".

Comment 15

Line 139- Does this mean that there is no evidence of editing in the database sequences?

Answer 15

Thanks for your remark. Indeed, this conclusion should be written here. We added the following: "…C-to-T mutations occurred as frequently as T-to-C mutations (Fig 4A), meaning that there is no strong evidence of APOBEC editing activity in the database sequences of this specific HCoV strain."

Comment 16

Line 145- Since the database analysis suggests that C-to-T editing by APOBEC is more characteristic of SARS-CoV-2 rather than HCoV-229E, is this a strain specific effect observed here?

Answer 16

Evidences on C-to-T editing in SARS-CoV, MERS-CoV and SARS-CoV-2 are supported in other studies that were cited in this article. As regarding HCoV-229E, we analyzed only HCoV-229E. We added a clarification in line 139 (answer to comment 14)

Comment 17

Line 140- 'that may be signatures of RNA editing' signatures of C-to-T RNA editing?

Answer 17

This is better describing the quoted study and the sentence was corrected..

Comment 18

Line 206- data to substantiate this claim?

Answer 18

Since no cell cycle analysis was performed in this study, we could give only a suggestion rather than a claim or a fact. The data is shone in figure 2A and more specifically in lines 191-195:

"In the present analysis, upregulation of cyclins and cell cycle regulation pathway was observed, together with downregulation of checkpoint regulation Growth 1 (G1) to Synthesis (S) phases, implying that cells enter the DNA synthesis phase. Functional annotation analysis supported these observations, where "Interphase", "Segregation of chromosomes", "G1/S phase transition", "S phase" and "M phase" annotations were upregulated at 6 HPI in MRC-5 cells (data not presented, IPA software)."

Comment 19

Line 375 and 377- Journal details missing

Answer 19

Citations were corrected. The study of Korber B et.al (citation #27) was a preprint version in biorxiv and we replaced it with an updated journal version that was published in Cell.

Comment 20

Line 481- and incubated

Answer 20

An unfortunate mistake that was corrected. Thank you..

Reviewer #2

Comment 1

at line 161 it might be useful to commend on the cholesterol biosynthesis pathway being downregulated both at early and late stages following HCoV-229E infection.

Answer 1

Thank you for emphasize these details. We added this sentence to the discussion

Comment 2

Could the upregulation of APOBEC3B (as antiviral reflection) in early stages of HCoV-229E infection be associated with the kinetics of viral copies that are found in and out of the host cells?

Answer 2

This is a very interesting point for discussion! Indeed APOBEC, as ISG could be associated with the kinetics of HCoV-229E, however, the lake in APOBEC C-toT editing activity in HCoV-229E genome may imply an evasion mechanism of the virus from this mutational mechanism.

Decision Letter 1

Binod Kumar

2 Feb 2021

Transcriptomic profiling and genomic mutational analysis of Human coronavirus (HCoV)-229E -infected human cells

PONE-D-20-36572R1

Dear Dr. Mandelboim,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Binod Kumar, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thanks for addressing all the comments and concerns raised earlier. The manuscript in the present format is acceptable for publication in PLoS One.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Acceptance letter

Binod Kumar

17 Feb 2021

PONE-D-20-36572R1

Transcriptomic profiling and genomic mutational analysis of Human coronavirus (HCoV)-229E -infected human cells

Dear Dr. Mandelboim:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Binod Kumar

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Data Availability Statement

    RNA-Seq library is available in the GEO repository (Accession number GSE155986).


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES